Medical Tourism in Shanghai: A Guide for International Patients

Home > Blog > Travel & Hospital Navigation

International patients may consider medical care in Shanghai for different reasons. Some face long waits for specialist assessment or surgery at home. Others are seeking a second opinion, a treatment pathway that is not routinely available in their country, or an alternative self-pay option for complex care.

Shanghai has a large network of public Grade 3A hospitals, specialist medical centers and private hospitals serving international patients. Accessing these institutions, however, requires more than choosing a hospital online. Medical records must be prepared appropriately, the relevant department must be identified, and the hospital must determine whether it can offer a review, appointment or treatment pathway.

Quick Answer

Medical tourism in Shanghai may provide international patients with access to specialist review, complex surgery, particle radiotherapy, cellular therapies and private international hospital services.

A structured pre-travel pathway normally involves:

• Compiling pathology reports, treatment summaries and DICOM imaging files according to the receiving institution’s current requirements.

• Identifying hospitals and specialist departments based on the documented diagnosis, clinical question, previous treatment and required level of care.

• Requesting a pre-arrival specialist review, multidisciplinary discussion or admission assessment where such a pathway is available.

• Confirming the appropriate visa or visa-free entry route according to the patient’s nationality, purpose of travel and expected length of stay.

• Reviewing estimated hospital charges, payment arrangements, insurance requirements and post-treatment follow-up before travel.

• 
  

Administrative preparation can help determine whether a relevant hospital pathway exists before the patient commits to international travel.、

Key Takeaways

• International patients consider Shanghai for reasons including treatment delays, high self-pay costs, limited local availability of specialised therapies and the need for an additional specialist opinion.

• Shanghai combines public Grade 3A academic hospitals, dedicated specialist centers and private hospitals with international patient services.

• Selected hospitals may offer pathways involving complex oncology, particle radiotherapy, robotic surgery, cellular therapy and advanced diagnostic review.

• Published self-pay figures may be lower than prices in some international markets, but costs vary substantially between hospitals, treatments and individual cases.

• Remote review, international admission and insurance direct billing are not universally available and must be confirmed for each institution and patient.

• Cross-border care requires careful coordination of medical records, travel fitness, visas, payments, insurance and follow-up arrangements.

An international patient discusses medical records with a clinician in Shanghai—illustrating how pre-travel specialist review and administrative coordination can support a more organised medical journey in China.

Why Do International Patients Consider Medical Tourism in Shanghai?

The reasons for seeking care overseas differ between countries and patients.

Delays in specialist assessment or treatment

In some healthcare systems, patients may experience extended waits for elective surgery, specialist assessment, advanced imaging or non-emergency treatment. Overseas care may be considered when a patient wants to explore whether an earlier institutional review or treatment appointment is available.

An overseas pathway should not be used to bypass medically necessary emergency care, and a faster appointment does not necessarily mean that a proposed treatment is clinically appropriate.

Limited availability of specialised treatment

Certain technologies or treatment products may not be routinely available in every country. Access may also be restricted by regulatory approval, public funding, insurance coverage, clinical trial availability or institutional eligibility criteria.

Shanghai contains specialist centers offering services such as proton and carbon-ion radiotherapy, complex oncological surgery and selected commercial cellular therapy pathways. Availability alone does not establish suitability: the receiving hospital must first evaluate the diagnosis and records.

The need for an additional specialist opinion

Patients with complex, rare, treatment-resistant or uncertain conditions may seek:

• Pathology re-review;

• Imaging review;

• A specialist second opinion;

• Multidisciplinary case discussion;

• Assessment of whether another treatment pathway should be considered.

The outcome of such a review may be that no additional treatment is recommended, that further testing is required, or that the patient is not suitable for the requested pathway.

Financial considerations

Self-pay hospital charges in China may be lower than those in some high-cost healthcare markets. However, price comparisons are difficult because quoted figures may include different:

• Treatment products;

• Professional fees;

• Hospital room categories;

• Lengths of stay;

• Diagnostic tests;

• Rehabilitation services;

• Complication-management arrangements.

Travel, accommodation, accompanying-family expenses and follow-up care must also be included when evaluating affordability.

How Can Clinical Volume Inform Hospital Selection?

Large tertiary hospitals in China may manage substantial patient and procedural volumes. Higher case volume can contribute to accumulated institutional experience in selected specialties, particularly when a hospital or department treats a concentrated number of similar cases.

Clinical volume alone does not prove:

• Superior treatment quality;

• Better individual outcomes;

• Suitability for a particular patient;

• Experience of the specific treating physician;

• Availability of an international patient pathway.

International patients should evaluate the relevant hospital, department and specialist rather than relying only on the overall size or national ranking of an institution.

MedBridgeNZ helps prepare records and identify potentially relevant institutional pathways based on the documented diagnosis and clinical question. Final clinical evaluation remains entirely with the receiving hospital and treating clinicians.

Pricing and Evidence Notes

The ranges below are drawn from publicly available institutional or third-party materials accessed in July 2026. They have not been independently confirmed as current quotations for an individual patient.

Published figures may refer to different products, indications, room categories and hospital pathways and are therefore not directly comparable.

Pathway	Illustrative Self-Pay Range	Source Basis
Selected commercial CAR-T pathways in China	USD 60,000–140,000	Published third-party estimate [11]; not a hospital quotation.
Proton therapy	USD 38,000–55,000	Published indicative range [12]; package inclusions vary.
Robotic prostatectomy	USD 8,000–16,000	Published third-party estimate [11]; not independently quoted for an individual case.

These figures should not be treated as quotations, price guarantees or evidence that a patient is eligible for the relevant treatment.

Before making a decision, patients should obtain an itemised written estimate from the receiving institution and confirm whether it includes:

• The treatment product or procedure;

• Specialist and anaesthesia fees;

• Hospital admission and room charges;

• Laboratory and imaging investigations;

• Pre-treatment preparation;

• Inpatient monitoring;

• Medicines and consumables;

• Management of expected complications;

• ICU care, if required;

• Follow-up appointments.

Flights, visas, accommodation, accompanying-family costs, rehabilitation and treatment required after returning home may be charged separately.

Relevant Shanghai Treatment Centers for International Patients

Shanghai’s medical infrastructure includes public Grade 3A hospitals, dedicated specialist centers and private hospitals offering international patient services. Patients can review our featured hospitals in Shanghai for an overview of selected institutions, hospital types and specialist departments.

Shanghai Proton and Heavy Ion Center

What it is:

A specialist radiation oncology facility equipped to provide both proton and carbon-ion radiotherapy.

Clinical function:

Particle therapy has physical dose-distribution characteristics that may reduce radiation exposure to selected surrounding tissues compared with conventional photon radiotherapy in appropriately selected cases.

Potential use cases:

Patients whose tumors may benefit from highly conformal radiotherapy, subject to:

• Tumor type;

• Tumor location;

• Disease stage;

• Previous radiation exposure;

• Treatment-planning considerations;

• The center’s current eligibility criteria.

Why it may matter:

For selected patients, proton or carbon-ion therapy may offer a different radiation dose-distribution approach when protecting nearby healthy structures is an important consideration.

The receiving radiation oncology team determines whether particle therapy offers a meaningful clinical advantage. It is not necessarily preferable to conventional radiotherapy for every patient or tumor.

Fudan University Shanghai Cancer Center

What it is:

A Grade 3A public hospital focused on oncology, clinical research and specialist cancer care.

Potential functions:

Depending on the disease, department and clinical indication, the center may offer or arrange:

• Specialist oncology review;

• Pathology review;

• Multidisciplinary discussion;

• Molecular or genomic testing;

• Targeted treatment pathways;

• Complex oncological surgery;

• Radiotherapy and systemic treatment assessment.

Potential use cases:

Patients seeking tertiary review for complex, uncommon or treatment-resistant solid tumors, subject to the relevant department’s capabilities and international patient arrangements.

Why it may matter:

Dedicated oncology institutions may provide access to subspecialist departments and concentrated experience with particular tumor types.

Suitability must be assessed at the hospital, department and individual-case level. A preliminary review does not guarantee admission or treatment.

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

What it is:

A comprehensive Grade 3A public teaching hospital with specialist departments covering hematology, endocrinology and complex internal medicine.

Potential functions:

Depending on diagnosis, department capacity and the hospital’s current pathway, selected patients may request specialist review for complex hematological or internal-medicine conditions.

Potential use cases:

Patients seeking tertiary hematology or internal-medicine review, subject to:

• The relevant department’s intake criteria;

• Current clinical capacity;

• Medical record completeness;

• International patient arrangements.

Why it may matter:

For selected cases, Ruijin Hospital may provide access to highly specialised departments and advanced treatment evaluation.

The availability of CAR-T assessment, remote review and international admission must be confirmed for each patient. The hospital’s clinical capabilities should not be interpreted as guaranteed access for every international applicant.

Jiahui International Hospital

What it is:

A 500-bed international hospital in Shanghai that reports JCI accreditation.

Institutional collaboration:

Mass General states that its collaboration with Jiahui began in 2012 and includes medical expertise and patient-care collaboration.

Potential use cases:

• Executive health screening;

• Outpatient specialist services;

• Routine and selected complex surgery;

• Oncology services;

• Care requiring an English-speaking administrative environment;

• Insurance direct billing where pre-authorised.

Why it may matter:

Private international hospitals may provide more familiar administrative, language and hospitality arrangements for international patients.

Accreditation, institutional collaboration, insurance acceptance and suitability for a particular treatment should be evaluated separately. Direct billing depends on the individual insurance policy, hospital department and issuance of a valid Guarantee of Payment.

What Is CAR-T Cell Therapy in This Context?

Chimeric Antigen Receptor T-cell therapy is an advanced cell therapy used mainly for selected hematological malignancies.

In June 2026, China’s National Medical Products Administration approved satricabtagene autoleucel, also known as satri-cel, a CLDN18.2-directed CAR-T product for a narrowly defined group of patients with[10].:

• CLDN18.2-positive disease;

• HER2-negative disease;

• Advanced gastric or gastroesophageal junction adenocarcinoma;

• Failure of at least two previous systemic treatment lines.

This approval does not mean that CAR-T is broadly available for all gastric cancers or solid tumors. Eligibility remains highly specific to:

• The confirmed diagnosis;

• Biomarker results;

• Previous treatments;

• Organ function;

• Infection status;

• Performance status;

• The approved product indication;

• The receiving institution’s protocol.

Published response rates vary substantially between diseases, products and patient populations. They should not be interpreted as guarantees of cure, durable response or long-term survival.

The clinical pathway may include:

1. Pathology and biomarker confirmation;

2. Review of previous treatment;

3. Initial eligibility assessment;

4. T-cell collection;

5. Product manufacturing;

6. Pre-infusion treatment;

7. CAR-T infusion;

8. Specialist inpatient monitoring;

9. Management of possible toxicity and complications.

The exact pathway differs between products and institutions.

Who May Request a Preliminary Hospital Review?

International patients may request an initial institutional review when they have:

• A confirmed diagnosis or clearly defined diagnostic question;

• Recent medical reports;

• Pathology results where relevant;

• Imaging reports and accessible DICOM files;

• A summary of previous treatment;

• A clear reason for seeking an overseas review.

The receiving hospital and treating clinicians—not MedBridgeNZ—determine whether a case is suitable for:

• Remote review;

• Specialist consultation;

• Further investigation;

• Admission;

• Surgery;

• Radiation therapy;

• Cellular therapy;

• Any other treatment pathway.

• 
  

Patients experiencing urgent deterioration, requiring ICU-level care or whose fitness for long-distance travel is uncertain should first seek advice from their treating clinician and, where relevant, an appropriately qualified medical transport provider.

Overseas options should never delay emergency or medically necessary local care.

What Administrative Challenges Do International Patients Commonly Face?

Medical record compatibility

Hospitals in different countries may use different:

• Medical terminology;

• Pathology reporting formats;

• Staging systems;

• Imaging platforms;

• Laboratory reference ranges;

• Electronic submission requirements.

A hospital may request additional records or a different file format before accepting a case for review.

DICOM imaging transfer

PDF imaging reports alone may not be sufficient for specialist review. Some departments require original DICOM files from CT, MRI, PET-CT or other examinations.

Large imaging files may need to be:

• Exported from the original imaging provider;

• Organised by date and modality;

• Uploaded through an approved transfer method;

• Checked to ensure the image series can be opened.

Language and translation

Translation requirements vary between hospitals and departments. Some international hospitals accept English-language records, while some public hospital departments may request selected documents in Chinese.

Translation supports administrative submission but does not replace pathology review, radiological interpretation or clinical assessment by the receiving specialists.

Identity and registration

Chinese hospitals commonly use real-name registration systems. International patients may need to provide:

• Passport information;

• A local or international contact number;

• A Chinese-language name entry;

• Insurance details;

• Advance payment or deposit information.

Requirements vary by hospital.

Payments and insurance

Private international hospitals and some public hospital international departments may accept major foreign-issued cards. Other public hospital departments may rely more heavily on:

• WeChat Pay;

• Alipay;

• Cash;

• Bank transfer;

• Advance deposits;

• Sequential pay-as-you-go settlement.

International insurance direct billing is more commonly available in private or international facilities, but it remains subject to:

• The patient’s policy;

• Regional coverage;

• The specific hospital and department;

• Pre-authorisation;

• Issuance of a Guarantee of Payment;

• Deductibles and excluded services.

Patients should obtain written confirmation rather than assuming that a foreign card or insurance policy will be accepted.

Request a Submission Readiness Check

Submit your diagnosis, latest treatment summary, pathology reports and imaging list. Our Patient Care Team can review the submitted file for apparent administrative gaps and explain which additional documents the receiving institution may request.

This is an administrative review only. It does not determine treatment eligibility or provide medical advice.

[Request a Submission Readiness Check]

Self-Arranged Access vs. an Administratively Coordinated Pathway

Pathway	More Suitable For	Main Considerations
Self-arranged access	Routine health checks, general outpatient appointments or patients familiar with the Chinese healthcare system	The patient independently manages hospital selection, registration, document requirements, translation, payments, visas and local logistics.
Administratively coordinated pathway	Complex oncology, particle therapy, specialist second opinions or planned surgical admissions	MedBridgeNZ coordinates record preparation, available specialist-review pathways, institutional communication and on-the-ground logistics.

Patients who require support with document preparation, institutional communication, travel planning or on-the-ground hospital navigation can review MedBridgeNZ’s cross-border medical coordination services.

Administrative coordination does not influence the hospital’s clinical decision or guarantee access to a requested treatment.

Representative International Patient Pathway

The following example is illustrative and does not describe a specific MedBridgeNZ patient.

1. Clinical context

A hypothetical international patient seeks an additional specialist opinion for relapsed or treatment-resistant B-cell lymphoma after receiving previous systemic treatment in their home country.

2. Records prepared for submission

The patient supplies:

• Pathology reports;

• Immunohistochemistry results;

• Relevant flow cytometry findings;

• Recent PET-CT imaging;

• Treatment summaries;

• Current medication information;

• Recent laboratory results.

MedBridgeNZ coordinates translation and document formatting according to the target institution’s current submission requirements.

3. Institutional review channel

Where a pre-arrival review is available and the case is accepted for submission, the prepared file may be sent to the relevant hospital department for:

• Individual specialist review;

• Multidisciplinary discussion;

• An international department assessment;

• A preliminary admission evaluation.

The form of review depends on the hospital’s current pathway.

4. Possible clinical review

The hospital’s clinicians may assess whether the documented diagnosis, disease markers, previous treatment and general medical condition support further evaluation of a cellular therapy or alternative treatment pathway.

The review may also conclude that:

• Additional testing is needed;

• Another department is more appropriate;

• The requested treatment is unsuitable;

• No meaningful overseas advantage has been identified.

A preliminary review does not guarantee admission or treatment eligibility.

5. Administrative next steps

If the receiving hospital confirms an appointment, further review or potential admission pathway, MedBridgeNZ can coordinate:

• Supporting hospital documentation where available;

• Visa and entry-process information;

• Appointment scheduling communication;

• Airport transfer;

• Accommodation planning;

• Real-name hospital registration;

• Bilingual on-site accompaniment;

• Payment and admission navigation.

Individual outcomes, treatment duration and scheduling depend on the patient’s condition and the receiving institution.

Important Clinical and Cross-Border Travel Risks

All advanced medical interventions carry risks, including infection, toxicity, bleeding, treatment failure and unexpected complications.

Cross-border care also introduces additional considerations.

Fitness to fly

Long-distance commercial flights may increase the risk of deep vein thrombosis or pulmonary embolism, particularly for patients with:

• Active cancer;

• Recent surgery;

• Reduced mobility;

• Previous blood clots;

• Significant cardiopulmonary disease.

A qualified clinician should determine whether the patient is medically stable to travel and whether additional precautions are required.

Timing of return travel

Patients should not assume that they can fly home immediately after surgery, cellular therapy or radiation treatment. The treating team should advise when commercial travel is medically appropriate.

Continuity of care

Before travelling, patients should discuss:

• Who will manage routine follow-up;

• How laboratory monitoring will be performed;

• Who will prescribe ongoing medication;

• How unexpected complications will be handled;

• Whether the local treating team can access and interpret the overseas records.

Medical records after treatment

Patients should request, where available:

• English or bilingual discharge summaries;

• Operative reports;

• Pathology results;

• Treatment protocols;

• Medication lists;

• Imaging files;

• Follow-up instructions.

Professional translation may be required for records issued only in Chinese.

Financial and insurance risk

Patients should confirm whether their insurance covers:

• Planned overseas treatment;

• Emergency complications abroad;

• Extended hospital admission;

• ICU care;

• Medical evacuation;

• Complications treated after returning home.

Unexpected admissions, delayed flights and extended accommodation may result in significant additional costs.

Privacy and data transfer

Medical records submitted internationally may be handled under different privacy and data-protection frameworks. Patients should understand:

• Who will receive their information;

• Why the information is being shared;

• How long it may be retained;

• How consent can be withdrawn where applicable;

• Which cross-border privacy rules may apply.

Legal rights and complaints

Legal rights, complaint procedures and dispute-resolution options may differ between jurisdictions and may depend on the hospital’s contractual terms.

Patients should review consent forms and financial agreements carefully and obtain independent legal advice where appropriate.

Frequently Asked Questions

1. How can international patients request a pre-arrival review from the Shanghai Proton and Heavy Ion Center?

MedBridgeNZ can help prepare DICOM imaging, pathology reports and treatment summaries according to the documents and file formats currently requested by the center.

Where a pre-arrival specialist review or eligibility assessment is available and the case is accepted for submission, MedBridgeNZ can coordinate the administrative submission. The center’s radiation oncology team determines whether further evaluation is appropriate.

2. What records are commonly requested for a preliminary CAR-T assessment?

Requirements vary according to the disease and hospital. Commonly requested records may include:

• Confirmed pathology;

• Immunohistochemistry;

• Biomarker or antigen-expression results;

• Flow cytometry where relevant;

• Molecular testing;

• Previous treatment summaries;

• Recent imaging;

• Laboratory results;

• Current medication information;

• Details of previous infections or significant complications.

The hospital may request additional testing before determining eligibility.

3. How does international insurance direct billing work?

The hospital normally checks whether it has a billing arrangement with the patient’s insurer or third-party administrator.

Before treatment, the insurer may need to issue a Guarantee of Payment specifying:

• Approved services;

• Financial limits;

• Deductibles;

• Co-payments;

• Excluded services;

• Authorised dates of treatment.

Direct billing is not guaranteed merely because a patient has international insurance.

4. What visa or entry route is required for medical care in China?

Requirements depend on:

• Nationality;

• Passport type;

• Purpose of travel;

• Expected treatment duration;

• Current Chinese immigration rules;

• Documents issued by the receiving hospital.

Visa and entry requirements depend on nationality, passport type, the stated purpose of travel, expected treatment duration and current Chinese immigration rules. For an overview of the available entry pathways and the documents that may be requested, see our China medical tourism visa guide

Patients should confirm the appropriate route with the relevant Chinese embassy or consulate and the receiving hospital before booking travel. Depending on the circumstances, an S2 visa or another lawful entry category may be considered, but the final determination belongs to the relevant Chinese authorities.

5. Can international patients use foreign-issued bank cards at Chinese hospitals?

Acceptance varies by hospital, department and payment counter.

Private international hospitals and some public hospital international departments may accept major international credit cards. Standard public hospital departments may rely more heavily on mobile payment, cash, bank transfer or advance deposits.

Patients should confirm payment arrangements before admission and maintain access to more than one payment method.

6. Can international patients use overseas health insurance in Shanghai?

Some private international hospitals and selected public hospital international departments work with international insurers or third-party administrators.

Coverage depends on:

• The insurance policy;

• Regional coverage;

• Pre-existing-condition exclusions;

• Annual or lifetime limits;

• The selected hospital;

• The treatment;

• Pre-authorisation.

Patients should obtain written confirmation from both the insurer and hospital before assuming direct billing will be available.

7. What health factors should be assessed before travelling for treatment?

Fitness to fly and suitability for international medical travel should be assessed by qualified treating clinicians.

Relevant considerations may include:

• Current medical stability;

• Oxygen requirements;

• Mobility limitations;

• Recent surgery;

• Infection risk;

• Blood-clot risk;

• Potential deterioration during travel;

• Availability of appropriate follow-up after returning home.

MedBridgeNZ does not make fit-to-fly or treatment-eligibility determinations.

8. How does MedBridgeNZ coordinate the translation of pathology and treatment records?

MedBridgeNZ coordinates translation and document formatting according to the receiving institution’s current administrative requirements.

The receiving pathologist, radiologist or treating specialist remains responsible for all clinical interpretation, diagnostic confirmation and treatment decisions.

Understanding the Administrative Pathway

Cross-border healthcare requires accurate records, realistic expectations and advance planning.

1. Initial case intake

Patients submit preliminary medical records and an imaging inventory.

MedBridgeNZ reviews the submitted material for apparent administrative gaps and coordinates document formatting and translation according to the intended institution’s requirements.

2. Hospital and specialist pathway identification

Based on the documented diagnosis, clinical question and submitted records, MedBridgeNZ identifies potentially relevant hospitals, departments or available review pathways.

With the patient’s authorisation, the prepared file may be submitted through the type of review channel currently offered by the receiving institution.

3. Pre-travel confirmation

Before travel, the patient should seek confirmation of:

• The proposed hospital or department;

• Appointment or review status;

• Whether admission has been accepted or remains provisional;

• Estimated hospital charges;

• Payment and deposit arrangements;

• Insurance pre-authorisation;

• Visa or entry requirements;

• Fitness to fly;

• Expected duration of stay;

• Post-treatment follow-up arrangements.

4. On-the-ground coordination

Once the receiving institution has confirmed an appointment, review or admission pathway, MedBridgeNZ can coordinate:

• Airport transfer;

• Accommodation;

• Hospital registration;

• Bilingual accompaniment;

• Administrative navigation;

• Appointment logistics;

• Payment-process assistance;

• Communication of hospital-issued documents.

MedBridgeNZ does not control clinical scheduling, hospital acceptance or treatment decisions.

Contact MedBridgeNZ

International patients seeking information about specialist review, medical record preparation, hospital routing or treatment-related travel coordination may submit an initial enquiry to MedBridgeNZ.

Our bilingual Patient Care Team aims to respond within one business day to explain:

• What documents are usually required;

• Which information appears to be missing;

• What type of institutional pathway may be available;

• What the next administrative steps may involve.

[Request a Submission Readiness Check]

Before uploading medical records, please review the MedBridgeNZ Privacy Notice and consent information regarding the collection and cross-border sharing of health information.

References

1. Shanghai Public Hospitals Embrace International Medical Tourism. https://english.shanghai.gov.cn/en-Latest-WhatsNew/20240923/85f2a95e516c42ce95643d1c9a39f59a.html

2. Shanghai Aims to Strengthen Global Medical Hub Status. https://english.shanghai.gov.cn/en-Latest-WhatsNew/20260305/64f641c0e82b408b8ba64c6cc276550e.html

3. Medical Tourism China Hospital Guide: A Six-Step Pathway for International Patients. https://www.medbridgenz.com/post/medical-tourism-china-hospital-guide-international-patients

4. China Medical Visa Guide for Medical Tourism. https://www.medbridgenz.com/china-medical-tourism-visa-guide

5. Conditions for Visa-Free Entry to China. https://auckland.china-consulate.gov.cn/eng/lsqz/gg/202605/t20260519_11912956.htm

6. Proton and Carbon Ion Therapy in China: 2026 Cost and Access Guide. https://www.medbridgenz.com/post/proton-carbon-ion-therapy-china

7. Jiahui International Hospital. https://www.massgeneral.org/cn/jiahui-en

8. International Patient Services | Jiahui International Hospital. https://mobile.jiahui.com/en/service/36

9. Direct Billing: Make Health Insurance Effortless. https://www.pacific-prime.cn/en/article/direct-billing-in-china/

10. Shanghai Pudong International Services. Pudong company's world-first solid tumor CAR-T therapy approved in China. Published June 24, 2026. Accessed July 2026. https://english.pudong.gov.cn/2026-06/24/c_1192878.htm

11. Sylk Health. Cancer Treatment Cost China vs US: Save 50-85% (2026). Published 2026. Accessed July 2026. https://sylkhealth.com/blog/articles/cancer-treatment-china-cost

12. MedBridgeNZ. Proton and Carbon Ion Therapy China: 2026 Cost & Access Guide. Published 2026. Accessed July 2026. https://www.medbridgenz.com/post/proton-carbon-ion-therapy-china

Information last reviewed in July 2026 and subject to change.

Disclaimer

MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide medical treatment, diagnosis, prescriptions or clinical advice. We do not determine treatment eligibility or guarantee hospital acceptance, appointment availability, treatment outcomes, visa approval, insurance coverage or final costs.

This content is provided for general informational purposes only and does not constitute medical, legal, immigration, insurance or financial advice. Patients should consult their treating clinicians and the relevant qualified authorities before pursuing cross-border medical care.